Genetic, biochemical, and clinical features of chronic granulomatous disease

Medicine

Volumn 79, Issue 3, 2000, Pages 170-200

  Segal, Brahm H ^a   Leto, Thomas L ^a   Gallin, John I ^a   Malech, Harry L ^a   Holland, Steven M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; COTRIMOXAZOLE; CYTOCHROME B558; GUANINE NUCLEOTIDE BINDING PROTEIN; RECOMBINANT GAMMA INTERFERON; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; CHRONIC GRANULOMATOUS DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; ENZYME REGULATION; GENETIC ASSOCIATION; GRANULOCYTE TRANSFUSION; HUMAN; HUMAN CELL; LEISHMANIA; MOUSE; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; FEMALE; GRANULOMATOUS DISEASE, CHRONIC; HETEROZYGOTE; HUMANS; INFECTION; INFLAMMATION; MALE; MICE; MODELS, BIOLOGICAL; MUTATION; NADPH OXIDASE;

EID: 0034128751     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-200005000-00004     Document Type: Review

References (440)

1. Abati A, Cajigas A, Holland SM, Solomon D. Chronic granulomatous disease of childhood: Respiratory cytology. Diagn Cytopathol 15: 98-102, 1996.
2. Abo A, Pick E, Hall A, Totty N, Teahan CG, Segal AW. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 353: 668-70, 1991.
3. Abo A, Webb MR, Grogan A, Segal AW. Activation of NADPH oxidase involves the dissociation of p21rac from its inhibitory GDP/GTP exchange protein (rhoGDI) followed by its translocation to the plasma membrane. Biochem J 298: 585-91, 1994.
4. Ahlin A, Elinder G, Palmblad J. Dose-dependent enhancements by interferon-gamma on functional responses of neutrophils from chronic granulomatous disease patients. Blood 89: 3396-401, 1997.
5. Ahlin A, Gyllenhammar H, Ringertz B, Palmblad J. Neutrophil membrane potential changes and homotypic aggregation kinetics are pH-dependent: Studies of chronic granulomatous disease. J Lab Clin Med 125: 392-401, 1995.
6. Ahmed S, Prigmore E, Govind S, Veryard C, Kozma R, Wientjes FB, Segal AW, Lim L. Cryptic Rac-binding and p21(Cdc42Hs/Rac)-activated kinase phosphorylation sites of NADPH oxidase component p67phox. J Biol Chem 273: 15693-701, 1998.
7. Al-Mehdi AB, Zhao G, Dodia C, Tozawa K, Costa K, Muzykantov V, Ross C, Blecha F, Dinauer M, Fisher AB. Endothelial NADPH oxidase as the source of oxidants in lungs exposed to ischemia or high K+> Circ Res 83: 730-37, 1998.
8. Albrecht H, Tschopp J, Jongeneel CV. Bcl-2 protects from oxidative damage and apoptotic cell death without interfering with activation of NF-kappa B by TNF. FEBS Lett 351: 45-48, 1994.
9. Aliabadi H, Gonzalez R, Quie PG. Urinary tract disorders in patients with chronic granulomatous disease. N Engl J Med 321: 706-8, 1989.
10. Aliev G, Bodin P, Burnstock G. Free radical generators cause changes in endothelial and inducible nitric oxide synthases and endothelin-1 immunoreactivity in endothelial cells from hyperlipidemic rabbits. Mol Genet Metab 63: 191-97, 1998.
11. Allen DM, Chng HH. Disseminated Mycobacterium flavescens in a probable case of chronic granulomatous disease. J Infect 26: 83-86, 1993.
12. Ambrosio G, Zweier JL, Becker LC. Apoptosis is prevented by administration of superoxide dismutase in dogs with reperfused myocardial infarction. Basic Res Cardiol 93: 94-96, 1998.
13. Anderson KL, Smith KA, Conners K, McKercher SR, Maki RA, Torbett BE. Myeloid development is selectively disrupted in PU.1 null mice. Blood 91: 3702-10, 1998.
14. Anderson KL, Smith KA, Pio F, Torbett BE, Maki RA. Neutrophils deficient in PU.1 do not terminally differentiate or become functionally competent. Blood 92: 1576-85, 1998.
15. Anderson MT, Staal FJ, Gitler C, Herzenberg LA. Separation of oxidant-initiated and redox-regulated steps in the NF-kappa B signal transduction pathway. Proc Natl Acad Sci U S A 91: 11527-31, 1994.
16. Aral B, de Saint Basile G, Al-Garawi S, Kamoun P, Ceballos-Picot I. Novel nonsense mutation in the hypoxanthine guanine phosphoribo-syltransferase gene and nonrandom X-inactivation causing Lesch-Nyhan syndrome in a female patient. Hum Mutat 7: 52-58, 1996.
17. Ariga T, Furuta H, Cho K, Sakiyama Y. Genetic analysis of 13 families with X-linked chronic granulomatous disease reveals a low proportion of sporadic patients and a high proportion of sporadic carriers Pediatr Res 44: 85-92, 1998.
18. Babior BM. NADPH oxidase: An update. Blood 93: 1464-76, 1999.
19. Babior BM, Kipnes RS. Superoxide-forming enzyme from human neutrophils: Evidence for a flavin requirement. Blood 50: 517-24, 1977.
20. Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barral A, Carvalho JS, Barral-Netto M, Brandely M, Silva L, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 322: 16-21, 1990.
21. Badwey JA, Curnutte JT, Karnovsky ML. cis-Polyunsaturated fatty acids induce high levels of superoxide production by human neutrophils. J Biol Chem 256: 12640-43, 1981.
22. Baehner RL, Kunkel LM, Monaco AP, Haines JL, Conneally PM, Palmer C, Heerema N, Orkin SH. DNA linkage analysis of X chromosome-linked chronic granulomatous disease. Proc Natl Acad Sci U S A 83: 3398-401, 1986.
23. Baehner RL, Nathan DG. Leukocyte oxidase: Defective activity in chronic granulomatous disease. Science 155: 835-36, 1967.
24. Baggiolini M, Boulay F, Badwey JA, Curnutte JT. Activation of neutrophil leukocytes: Chemoattractant receptors and respiratory burst. Faseb J 7: 1004-10, 1993.
25. Baggiolini M, Dewald B, Schnyder J, Ruch W, Cooper PH, Payne TG. Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues. Exp Cell Res 169: 408-18, 1987.
26. Barbujani G, Russo A, Danieli GA, Spiegler AW, Borkowska J, Petrusewicz IH. Segregation analysis of 1885 DMD families: Significant departure from the expected proportion of sporadic cases. Hum Genet 84: 522-26, 1990.
27. Barchowsky A, Munro SR, Morana SJ, Vincenti MP, Treadwell M. Oxidant-sensitive and phosphorylation-dependent activation of NF-kappa B and AP-1 in endothelial cells. Am J Physiol 269: L829-36, 1995.
28. Barton LL, Johnson CR. Discoid lupus erythematosus and X-linked chronic granulomatous disease. Pediatr Dermatol 3: 376-79, 1986.
29. Barton LL, Moussa SL, Villar RG, Hulett RL. Gastrointestinal complications of chronic granulomatous disease: Case report and literature review. Clin Pediatr (Phila) 37: 231-36, 1998.
30. Battat L, Francke U. Nsi I RFLP at the X-linked chronic granulomatous disease locus (CYBB). Nucleic Acids Res 17: 3619, 1989.
31. Becker S, Wasser S, Hauses M, Hossle JP, Ott MG, Dinauer MC, Ganser A, Hoelzer D, Seger R, Grez M. Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells. Hum Gene Ther 9: 1561-70, 1998.
32. Berendes H, Bridges RA, Good RA. A fatal granulomatous disease of childhood: The clinical study of a new syndrome. Minn Med 40: 309-12, 1957.
33. Bernardi F, Marchetti G, Bertagnolo V, Faggioli L, Volinia S, Patracchini P, Bartolai S, Vannini F, Felloni L, Rossi L, et al. RFLP analysis in families with sporadic hemophilia A. Estimate of the mutation ratio in male and female gametes. Hum Genet 76: 253-56, 1987.
34. Bhunia AK, Han H, Snowden A, Chatterjee S. Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells. J Biol Chem 272: 15642-49, 1997.
35. Bjorgvinsdottir H, Ding C, Pech N, Gifford MA, Li LL, Dinauer MC. Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease. Blood 89: 41-48, 1997.
36. Blackwell TS, Blackwell TR, Holden EP, Christman BW, Christman JW. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol 157: 1630-37, 1996.
37. Bladier C, Wolvetang EJ, Hutchinson P, de Haan JB, Kola I. Response of a primary human fibroblast cell line to H2O2: Senescence-like growth arrest or apoptosis? Cell Growth Differ 8: 589-98, 1997.
38. Bokoch GM, Quilliam LA, Bohl BP, Jesaitis AJ, Quinn MT. Inhibition of Rap1A binding to cytochrome b558 of NADPH oxidase by phosphorylation of Rap1A. Science 254: 1794-96, 1991.
39. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89: 3503-21, 1997.
40. Borregaard N, Cross AR, Herlin T, Jones OT, Segal AW, Valerius NH. A variant form of X-linked chronic granulomatous disease with normal nitroblue tetrazolium slide test and cytochrome b. Eur J Clin Invest 13: 243-48, 1983.
41. Borregaard N, Heiple JM, Simons ER, Clark RA. Subcellular localization of the b-cytochrome component of the human neutrophil microbicidal oxidase: Translocation during activation. J Cell Biol 97: 52-61, 1983.
42. Bouin AP, Grandvaux N, Vignais PV, Fuchs A. p40phox is phosphorylated on threonine 154 and serine 315 during activation of the phagocyte NADPH oxidase. Implication of a protein kinase c-type kinase in the phosphorylation process. J Biol Chem 273: 30097-103, 1998.
43. Brandrup F, Koch C, Petri M, Schiodt M, Johansen KS. Discoid lupus erythematosus-like lesions and stomatitis in female carriers of X-linked chronic granulomatous disease. Br J Dermatol 104: 495-505, 1981.
44. Bridges RA, Berendes H, Good RA. A fatal granulomatous disease of childhood. Am J Dis Child 97: 387-408, 1959.
45. Bromberg Y, Pick E. Unsaturated fatty acids stimulate NADPH-dependent superoxide production by cell-free system derived from macrophages. Cell Immunol 88: 213-21, 1984.
46. Brumell JH, Burkhardt AL, Bolen JB, Grinstein S. Endogenous reactive oxygen intermediates activate tyrosine kinases in human neutrophils J Biol Chem 271: 1455-61, 1996.
47. Brzica SM Jr, Pineda AA, Taswell HF, Rhodes KH. Chronic granulomatous disease and the Mcleod phenotype. Successful treatment of infection with granulocyte transfusions resulting in subsequent hemolytic transfusion reaction. Mayo Clin Proc 52: 153-56, 1977.
48. Buescher ES, Ailing DW, Gallin JI. Use of an X-linked human neutrophil marker to estimate timing of lyonization and size of the dividing stem cell pool. J Clin Invest 76: 1581-84, 1985.
49. Buescher ES, Gallin JI. Leukocyte transfusions in chronic granulomatous disease: Persistence of transfused leukocytes in sputum. N Engl J Med 307: 800-803, 1982.
50. Bujak JS, Kwon-Chung KJ, Chusid MJ. Osteomyelitis and pneumonia in a boy with chronic granulomatous disease of childhood caused by a mutant strain of Aspergillus nidulans. Am J Clin Pathol 61: 361-67, 1974.
51. Bulkley GB. Physiology of reactive oxidant-mediated signal transduction: An overview. Biochem Soc Trans 25: 804-12, 1997.
52. Bunnell E, Pacht ER. Oxidized glutathione is increased in the alveolar fluid of patients with the adult respiratory distress syndrome. Am Rev Respir Dis 148: 1174-78, 1993.
53. Buttke TM, Sandstrom PA. Redox regulation of programmed cell death in lymphocytes. Free Radic Res 22: 389-97, 1995.
54. Calvino MC, Maldonado MS, Otheo E, Munoz A, Couselo JM, Burgaleta C. Bone marrow transplantation in chronic granulomatous disease. Eur J Pediatr 155: 877-79, 1996.
55. Candotti F, Johnston JA, Puck JM, Sugamura K, O'Shea JJ, Blaese RM. Retroviral-mediated gene correction for X-linked severe combined immunodeficiency. Blood 87: 3097-102, 1996.
56. Caron E, Hall A. Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science 282: 1717-21, 1998.
57. Carson MJ, Chadwick DL, Brubaker RA, Cleland RS, Landing BH. Thirteen boys with progressive septic granulomatosis. Pediatrics 35: 405-12, 1965.
58. Casale TB, Macher AM, Fauci AS. Concomitant pulmonary aspergillosis and nocardiosis in a patient with chronic granulomatous disease of childhood. South Med J 77: 274-75, 1984.
59. Casimir CM, Bu-Ghanim HN, Rodaway AR, Bentley DL, Rowe P, Segal AW. Autosomal recessive chronic granulomatous disease caused by deletion at a dinucleotide repeat. Proc Natl Acad Sci U S A 88: 2753-57, 1991.
60. Casson DH, Riordan FA, Ladusens EJ. Aspergillus endocarditis in chronic granulomatous disease. Acta Paediatr 85: 758-59, 1996.
61. Chang YC, Segal BH, Holland SM, Miller GF, Kwon-Chung KJ. Virulence of catalase-deficient Aspergillus nidulans in p47phox-/-mice. Implications for fungal pathogenicity and host defense in chronic granulomatous disease. J Clin Invest 101: 1843-50, 1998.
62. Chanock SJ, Faust LR, Barrett D, Bizal C, Maly FE, Newburger PE, Ruedi JM, Smith RM, Babior BM. O2-production by B lymphocytes lacking the respiratory burst oxidase subunit p47phox after transfection with an expression vector containing a p47phox cDNA. Proc Natl Acad Sci U S A 89: 10174-77, 1992.
63. Chin TW, Stiehm ER, Falloon J, Gallin JI. Corticosteroids in treatment of obstructive lesions of chronic granulomatous disease. J Pediatr 111: 349-52, 1987.
64. Chuang TH, Bohl BP, Bokoch GM. Biologically active lipids are regulators of Rac.GDI complexation. J Biol Chem 268: 26206-11, 1993.
65. Chusid MJ, Parrillo JE, Fauci AS. Chronic granulomatous disease. Diagnosis in a 27-year-old man with Mycobacterium fortuitum. Jama 233: 1295-96, 1975.
66. Clark RA, Klebanoff SJ. Chemotactic factor inactivation by the myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest 64: 913-20, 1979.
67. Clark RA, Malech HL, Gallin JI, Nunoi H, Volpp BD, Pearson DW, Nauseef WM, Cumutte JT. Genetic variants of chronic granulomatous disease: Prevalence of deficiencies of two cytosolic components of the NADPH oxidase system. N Engl J Med 321: 647-52, 1989.
68. Clark RA, Volpp BD, Leidal KG, Nauseef WM. Two cytosolic components of the human neutrophil respiratory burst oxidase translocate to the plasma membrane during cell activation. J Clin Invest 85: 714-21, 1990.
69. Clarke JT, Greer WL, Strasberg PM, Pearce RD, Skomorowski MA, Ray PN. Hunter disease (mucopolysaccharidosis type II) associated with unbalanced inactivation of the X chromosomes in a karyotypically normal girl. Am J Hum Genet 49: 289-97, 1991.
70. Cohen MS, Isturiz RE, Malech HL, Root RK, Wilfert CM, Gutman L, Buckley RH. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med 71: 59-66, 1981.
71. Cominacini L, Garbin U, Pasini AF, Davoli A, Campagnola M, Contessi GB, Pastorino AM, Lo Cascio V. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic Biol Med 22: 117-27, 1997.
72. Condino-Neto A, Whitney C, Newburger PE. Dexamethasone but not indomethacin inhibits human phagocyte nicotinamide adenine dinucleotide phosphate oxidase activity by down-regulating expression of genes encoding oxidase components. J Immunol 161: 4960-67, 1998.
73. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178: 2243-47, 1993.
74. Coxon A, Rieu P, Barkalow FJ, Askari S, Sharpe AH, von Andrian UH, Arnaout MA, Mayadas TN. A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: A homeostatic mechanism in inflammation. Immunity 5: 653-66, 1996.
75. Crockard AD, Thompson JM, Boyd NA, Haughton DJ, McCluskey DR, Turner CP. Diagnosis and carrier detection of chronic granulomatous disease in five families by flow cytometry. Int Arch Allergy Immunol 114: 144-52, 1997.
76. Cross AR, Curnutte JT, Heyworth PG. Hematologically important mutations: The autosomal recessive forms of chronic granulomatous disease. Blood Cells Mol Dis 22: 268-70, 1996.
77. Cross AR, Curnutte JT, Rae J, Heyworth PG. Hematologically important mutations: X-linked chronic granulomatous disease. Blood Cells Mol Dis 22: 90-95, 1996.
78. Cross AR, Heyworth PG, Rae J, Curnutte JT. A variant X-linked chronic granulomatous disease patient (X91+) with partially functional cytochrome b. J Biol Chem 270: 8194-200, 1995.
79. Cross AR, Jones OT, Harper AM, Segal AW. Oxidation-reduction properties of the cytochrome b found in the plasma-membrane fraction of human neutrophils. A possible oxidase in the respiratory burst. Biochem J 194: 599-606, 1981.
80. Cross AR, Parkinson JF, Jones OT. Mechanism of the superoxide-producing oxidase of neutrophils. O2 is necessary for the fast reduction of cytochrome b-245 by NADPH. Biochem J 226: 881-84, 1985.
81. Cross AR, Rae J, Curnutte JT. Cytochrome b-245 of the neutrophil superoxide-generating system contains two nonidentical hemes. Potentiometric studies of a mutant form of gp91phox. J Biol Chem 270: 17075-77, 1995.
82. Curnutte JT. Activation of human neutrophil nicotinamide adenine dinucleotide phosphate, reduced (triphosphopyridine nucleotide, reduced) oxidase by arachidonic acid in a cell-free system. J Clin Invest 75: 1740-43, 1985.
83. Curnutte JT, Hopkins PJ, Kuhl W, Beutler E. Studying X inactivation [letter]. Lancet 339: 749, 1992.
84. Curnutte JT, Kuver R, Babior BM. Activation of the respiratory burst oxidase in a fully soluble system from human neutrophils. J Biol Chem 262: 6450-52, 1987.
85. Curnutte JT, Kuver R, Scott PJ. Activation of neutrophil NADPH oxidase in a cell-free system. Partial purification of components and characterization of the activation process. J Biol Chem 262: 5563-69, 1987.
86. Curnutte JT, Scott PJ, Mayo LA. Cytosolic components of the respiratory burst oxidase: Resolution of four components, two of which are missing in complementing types of chronic granulomatous disease. Proc Natl Acad Sci U S A 86: 825-29, 1989.
87. Dagher MC, Fuchs A, Bourmeyster N, Jouan A, Vignais PV. Small G proteins and the neutrophil NADPH oxidase. Biochimie 77: 651-60, 1995.
88. Dana R, Leto TL, Malech HL, Levy R. Essential requirement of cytosolic phospholipase A2 for activation of the phagocyte NADPH oxidase. J Biol Chem 273: 441-45, 1998.
89. Danziger RN, Goren AT, Becker J, Greene JM, Douglas SD. Outpatient management with oral corticosteroid therapy for obstructive conditions in chronic granulomatous disease. J Pediatr 122: 303-5, 1993.
90. de Mendez I, Adams AG, Sokolic RA, Malech HL, Leto TL. Multiple SH3 domain interactions regulate NADPH oxidase assembly in whole cells. Embo J 15: 1211-20, 1996.
91. de Mendez I, Garrett MC, Adams AG, Leto TL. Role of p67-phox SH3 domains in assembly of the NADPH oxidase system. J Biol Chem 269: 16326-32, 1994.
92. de Mendez I, Homayounpour N, Leto TL. Specificity of p47phox SH3 domain interactions in NADPH oxidase assembly and activation. Mol Cell Biol 17: 2177-85, 1997.
93. de Mendez I, Leto TL. Functional reconstitution of the phagocyte NADPH oxidase by transfection of its multiple components in a heterologous system. Blood 85: 1104-10, 1995.
94. DeLeo FR, Nauseef WM, Jesaitis AJ, Burritt JB, Clark RA, Quinn MT. A domain of p47phox that interacts with human neutrophil flavocytochrome b558. J Biol Chem 270: 26246-51, 1995.
95. DeLeo FR, Renee J, McCormick S, Nakamura M, Apicella M, Weiss JP, Nauseef WM. Neutrophils exposed to bacterial hpopolysaccharide upregulate NADPH oxidase assembly. J Clin Invest 101: 455-63, 1998.
96. DeLeo FR, Yu L, Burritt JB, Loetterle LR, Bond CW, Jesaitis AJ, Quinn MT. Mapping sites of interaction of p47-phox and flavocytochrome b with random-sequence peptide phage display libraries. Proc Natl Acad Sci U S A 92: 7110-14, 1995.
97. Depalma L, Leitman SF, Carter CS, Gallin JI. Granulocyte transfusion therapy in a child with chronic granulomatous disease and multiple red cell alloantibodies. Transfusion 29: 421-23, 1989.
98. Dewald B, Thelen M, Baggiolini M. Two transduction sequences are necessary for neutrophil activation by receptor agonists. J Biol Chem 263: 16179-84, 1988.
99. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med 337: 408-16, 1997.
100. Didsbury J, Weber RF, Bokoch GM, Evans T, Snyderman R. rac, a novel ras-related family of proteins that are botulinum toxin substrates. J Biol Chem 264: 16378-82, 1989.
101. Diekmann D, Abo A, Johnston C, Segal AW, Hall A. Interaction of Rac with p67phox and regulation of phagocytic NADPH oxidase activity. Science 265: 531-33, 1994.
102. Dinauer MC, Curnutte JT, Rosen H, Orkin SH. A missense mutation in the neutrophil cytochrome b heavy chain in cytochrome-positive X-linked chronic granulomatous disease. J Clin Invest 84: 2012-16, 1989.
103. Dinauer MC, Orkin SH, Brown R, Jesaitis AJ, Parkos CA. The glycoprotein encoded by the X-linked chronic granulomatous disease locus is a component of the neutrophil cytochrome b complex. Nature 327: 717-20, 1987.
104. Dinauer MC, Pierce EA, Bruns GA, Curnutte JT, Orkin SH. Human neutrophil cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. J Clin Invest 86: 1729-37, 1990.
105. Dinauer MC, Pierce EA, Erickson RW, Muhlebach TJ, Messner H, Orkin SH, Seger RA, Curnutte JT. Point mutation in the cytoplasmic domain of the neutrophil p22-phox cytochrome b subunit is associated with a nonfunctional NADPH oxidase and chronic granulomatous disease. Proc Natl Acad Sci U S A 88: 11231-35, 1991.
106. Ding C, Kume A, Bjorgvinsdottir H, Hawley RG, Pech N, Dinauer MC. High-level reconstitution of respiratory burst activity in a human X-linked chronic granulomatous disease (X-CGD) cell line and correction of murine X-CGD bone marrow cells by retroviral-mediated gene transfer of human gp91phox. Blood 88: 1834-40, 1996.
107. Dorman SE, Gill VJ, Gallin JI, Holland SM. Burkholderia pseudomallei infection in a Puerto Rican patient with chronic granulomatous disease: Case report and review of occurrences in the Americas. Clin Infect Dis 26: 889-94, 1998.
108. Dorman SE, Holland SM. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J Clin Invest 101: 2364-69, 1998.
109. Dorseuil O, Reibel L, Bokoch GM, Camonis J, Gacon G. The Rac target NADPH oxidase p67phox interacts preferentially with Rac2 rather than Rac1. J Biol Chem 271: 83-88, 1996.
110. Dorseuil O, Vazquez A, Lang P, Bertoglio J, Gacon G, Leca G. Inhibition of superoxide production in B lymphocytes by rac antisense oligonucleotides. J Biol Chem 267: 20540-42, 1992.
111. Dougherty SH, Peterson PK, Simmons RL. Granulocyte transfusion as adjunctive therapy for qualitative granulocytopenia. Multiple liver abscesses in a patient with chronic granulomatous disease. Arch Surg 118:873-74, 1983.
112. Dusi S, Della Bianca V, Grzeskowiak M, Rossi F. Relationship between phosphorylation and translocation to the plasma membrane of p47phox and p67phox and activation of the NADPH oxidase in normal and Ca(2+)-depletedhumanneutrophils. Biochem J 290: 173-78, 1993.
113. Dusi S, Donini M, Rossi F. Mechanisms of NADPH oxidase activation: Translocation of p40phox, Rac1 and Rac2 from the cytosol to the membranes in human neutrophils lacking p47phox or p67phox. Biochem J 314: 409-12, 1996.
114. Dusi S, Nadalini KA, Donini M, Zentilin L, Wientjes FB, Roos D, Giacca M, Rossi F. Nicotinamide-adenine dinucleotide phosphate oxidase assembly and activation in EBV-transformed B lymphoblastoid cell lines of normal and chronic granulomatous disease patients. J Immunol 161: 4968-74, 1998.
115. Dusi S, Rossi F. Activation of NADPH oxidase of human neutrophils involves the phosphorylation and the translocation of cytosolic p67phox. Biochem J 296: 367-71, 1993.
116. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, van der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391: 393-97, 1998.
117. Eklund EA, Jalava A, KakarR. PU. 1, interferon regulatory factor 1, and interferon consensus sequence-binding protein cooperate to increase gp91phox expression. J Biol Chem 273: 13957-65, 1998.
118. Eklund EA, Marshall M, Gibbs JB, Crean CD, Gabig TG. Resolution of a low molecular weight G protein in neutrophil cytosol required for NADPH oxidase activation and reconstitution by recombinant Krev-1 protein. J Biol Chem 266: 13964-70, 1991.
119. Eklund EA, Skalnik DG. Characterization of a gp91-phox promoter element that is required for interferon gamma-induced transcription. J Biol Chem 270: 8267-73, 1995.
120. El Benna J, Dang PM, Gaudry M, Fay M, Morel F, Hakim J, Gougerot-Pocidalo MA. Phosphorylation of the respiratory burst oxidase subunit p67phox during human neutrophil activation. Regulation by protein kinase C-dependent and independent pathways. J Biol Chem 272: 17204-8, 1997.
121. El Benna J, Faust LP, Babior BM. The phosphorylation of the respiratory burst oxidase component p47phox during neutrophil activation. Phosphorylation of sites recognized by protein kinase C and by proline-directed kinases. J Biol Chem 269: 23431-36, 1994.
122. El Benna J, Faust RP, Johnson JL, Babior BM. Phosphorylation of the respiratory burst oxidase subunit p47phox as determined by two-dimensional phosphopeptide mapping. Phosphorylation by protein kinase C, protein kinase A, and a mitogen-activated protein kinase. J Biol Chem 271: 6374-78, 1996.
123. Emmendorffer A, Lohmann-Matthes ML, Roesler J. Kinetics of transfused neutrophils in peripheral blood and BAL fluid of a patient with variant X-linked chronic granulomatous disease. Eur J Haematol 47: 246-52, 1991.
124. Emmendorffer A, Nakamura M, Rothe G, Spiekermann K, Lohmann-Matthes ML, Roesler J. Evaluation of flow cytometric methods for diagnosis of chronic granulomatous disease variants under routine laboratory conditions. Cytometry 18: 147-55, 1994.
125. Esterly JR, Sturner WQ, Esterly NB, Windhorst DB. Disseminated BCG in twin boys with presumed chronic granulomatous disease of childhood. Pediatrics 48: 141-44, 1971.
126. Evans TJ, Buttery LD, Carpenter A, Springall DR, Polak JM, Cohen J. Cytokine-treated human neutrophils contain inducible nitric oxide synthase that produces nitration of ingested bacteria. Proc Natl Acad Sci U S A 93: 9553-58, 1996.
127. Ezekowitz RA, Dinauer MC, Jaffe HS, Orkin SH, Newburger PE. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med 319: 146-51, 1988.
128. Ezekowitz RA, Orkin SH, Newburger PE. Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J Clin Invest 80: 1009-16, 1987.
129. Fan J, Marshall JC, Jimenez M, Shek PN, Zagorski J, Rotstein OD. Hemorrhagic shock primes for increased expression of cytokine-induced neutrophil chemoattractant in the lung: Role in pulmonary inflammation following lipopolysaccharide. J Immunol 161: 440-47, 1998.
130. Fanconi S, Seger R, Gmur J, Willi U, Schaer G, Spiess H, Otto R, Hitzig WH. Surgery and granulocyte transfusions for life-threatening infections in chronic granulomatous disease. Helv Paediatr Acta 40: 277-84, 1985.
131. Fang W, Nath KA, Mackey MF, Noelle RJ, Mueller DL, Behrens TW. CD40 inhibits B cell apoptosis by upregulating bcl-xL expression and blocking oxidant accumulation. Am J Physiol 272: C950-56, 1997.
132. Faust LR, El Benna J, Babior BM, Chanock SJ. The phosphorylation targets of p47phox, a subunit of the respiratory burst oxidase. Functions of the individual target serines as evaluated by site-directed mutagenesis. J Clin Invest 96: 1499-505, 1995.
133. Feinman R, Qiu WQ, Pearse RN, Nikolajczyk BS, Sen R, Sheffery M, Ravetch JV. PU.1 and an HLH family member contribute to the myeloid-specific transcription of the Fc gamma RIIIA promoter. Embo J 13: 3852-60, 1994.
134. Fialkow L, Chan CK, Rotin D, Grinstein S, Downey GP. Activation of the mitogen-activated protein kinase signaling pathway in neutrophils. Role of oxidants. J Biol Chem 269: 31234-42, 1994.
135. Fijen CA, Schrama J, Kuijper EJ, Boiron P, Gerritsen W, Speelman P. Infection due to Nocardia farcinica in a woman with chronic granulomatous disease. Clin Infect Dis 26: 222-24, 1998.
136. Finegold AA, Shatwell KP, Segal AW, Klausner RD, Dancis A. Intramembrane bis-heme motif for transmembrane electron transport conserved in a yeast iron reductase and the human NADPH oxidase. J Biol Chem 271: 31021-24, 1996.
137. Finlay AY, Kingston HM, Holt PJ. Chronic granulomatous disease carrier geno-dermatosis (CGDCGD). Clin Genet 23: 276-80, 1983.
138. Flohe L, Brigelius-Flohe R, Saliou C, Traber MG, Packer L. Redox regulation of NF-kappa B activation. Free Radic Biol Med 22: 1115-26, 1997.
139. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178: 2249-54, 1993.
140. Forbes LV, Moss SJ, Segal AW. Phosphorylation of p67phox in the neutrophil occurs in the cytosol and is independent of p47phox. FEBS Lett 449: 225-29, 1999.
141. Forbes LV, Truong O, Wientjes FB, Moss SJ, Segal AW. The major phosphorylation site of the NADPH oxidase component p67phox is Thr233. Biochem J 338: 99-105, 1999.
142. Foster CB, Lehrnbecher T, Mol F, Steinberg SM, Venzon DJ, Walsh TJ, Noack D, Rae J, Winkelstein JA, Curnutte JT, Chanock SJ. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest 102: 2146-55, 1998.
143. Francke U, Ochs HD, Darras BT, Swaroop A. Origin of mutations in two families with X-linked chronic granulomatous disease. Blood 76: 602-6, 1990.
144. Fuchs A, Dagher MC, Faure J, Vignais PV. Topological organization of the cytosolic activating complex of the superoxide-generating NADPH-oxidase. Pinpointing the sites of interaction between p47phoz, p67phox and p40phox using the two-hybrid system. Biochim Biophys Acta 1312: 39-47, 1996.
145. Fuchs A, Dagher MC, Vignais PV. Mapping the domains of interaction of p40phox with both p47phox and p67phox of the neutrophil oxidase complex using the two-hybrid system. J Biol Chem 270: 5695-97, 1995.
146. Fujii H, Ichimori K, Hoshiai K, Nakazawa H. Nitric oxide inactivates NADPH oxidase in pig neutrophils by inhibiting its assembling process. J Biol Chem 272: 32773-78, 1997.
147. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q 4th, Taylor WR, Harrison DG, de Leon H, Wilcox JN, Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80: 45-51, 1997.
148. Gabig TG, Crean CD, Mantel PL, Rosli R. Function of wild-type or mutant Rac2 and Rap1a GTPases in differentiated HL60 cell NADPH oxidase activation. Blood 85: 804-11, 1995.
149. Gagnon C, Leblond FA, Filep JG. Peroxynitrite production by human neutrophils, monocytes and lymphocytes challenged with lipopolysaccharide. FEBS Lett 431: 107-10, 1998.
150. Galis ZS, Asanuma K, Godin D, Meng X. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: New target for antioxidant therapy? Circulation 97: 2445-53, 1998.
151. Gallin JI, Buescher ES. Abnormal regulation of inflammatory skin responses in male patients with chronic granulomatous disease. Inflammation 7: 227-32, 1983.
152. Gallin JI, Buescher ES, Seligmann BE, Nath J, Gaither T, Katz P. NIH conference. Recent advances in chronic granulomatous disease. Ann Intern Med 99: 657-74, 1983.
153. Gallin JI, Farber JM, Holland SM, Nutman TB. Interferon-gamma in the management of infectious diseases [clinical conference]. Ann Intern Med 123: 216-24, 1995.
154. Gallo RL, Ono M, Povsic T, Page C, Eriksson E, Klagsbrun M, Bernfield M. Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc Natl Acad Sci U S A 91: 11035-39, 1994.
155. Garioch JJ, Sampson JR, Seywright M, Thomson J. Dermatoses in five related female carriers of X-linked chronic granulomatous disease. Br J Dermatol 121: 391-96, 1989.
156. Geiszt M, Kapus A, Nemet K, Farkas L, Ligeti E. Regulation of capacitative Ca2+ influx in human neutrophil granulocytes. Alterations in chronic granulomatous disease. J Biol Chem 272: 26471-78, 1997.
157. Gomez-Cambronero J, Keire P. Phospholipase D: A novel major player in signal transduction. Cell Signal 10: 387-97, 1998.
158. Goode HF, Webster NR. Free radicals and antioxidants in sepsis. Crit Care Med 21: 1770-76, 1993.
159. Gorlach A, Lee PL, Roesler J, Hopkins PJ, Christensen B, Green ED, Chanock SJ, Curnutte JT. A p47-phox pseudogene carries the most common mutation causing p47-phox-deficient chronic granulomatous disease. J Clin Invest 100: 1907-18, 1997.
160. Gorlin JB. Identification of (CA/GT)n polymorphisms within the X-linked chronic granulomatous disease (X-CGD) gene: Utility for prenatal diagnosis. J Pediatr Hematol Oncol 20: 112-19, 1998.
161. Gotoh Y, Cooper JA. Reactive oxygen species-and dimerization-induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha signal transduction. J Biol Chem 273: 17477-82, 1998.
162. Hafner J, Enderlin A, Seger RA, Wuthrich B, Bruckner-Tudermann L, Panizzoni P, Burg G. Discoid lupus erythematosus-like lesions in carriers of X-linked chronic granulomatous disease [letter; comment]. Br J Dermatol 127: 446-47, 1992.
163. Hahn SM, Mitchell JB, Shacter E. Tempol inhibits neutrophil and hydrogen peroxide-mediated DNA damage. Free Radic Biol Med 23: 879-84, 1997.
164. Hamasaki T, Sakano T, Kobayashi M, Sakura N, Ueda K, Usui T. Leukotriene B4 metabolism in neutrophils of patients with chronic granulomatous disease: Phorbol myristate acetate decreases endogenous leukotriene B4 via NADPH oxidase-dependent mechanism. Eur J Clin Invest 19: 404-11, 1989.
165. Hamers MN, de Boer M, Meerhof LJ, Weening RS, Roos D. Complementation in monocyte hybrids revealing genetic heterogeneity in chronic granulomatous disease. Nature 307: 553-55, 1984.
166. Harper AM, Chaplin MF, Segal AW. Cytochrome b-245 from human neutrophils is a glycoprotein. Biochem J 227: 783-88, 1985.
167. Hata K, Ito T, Takeshige K, Sumimoto H. Anionic amphiphile-independent activation of the phagocyte NADPH oxidase in a cell-free system by p47phox and p67phox, both in C terminally truncated forms. Implication for regulatory Src homology 3 domain-mediated interactions. J Biol Chem 273: 4232-36, 1998.
168. Henderson LM. Role of histidines identified by mutagenesis in the NADPH oxidase-associated H+ channel. J Biol Chem 273: 33216-23, 1998.
169. Henderson LM, Thomas S, Banting G, Chappell JB. The arachidonate-activatable, NADPH oxidase-associated H+ channel is contained within the multi-membrane-spanning N-terminal region of gp91-phox. Biochem J 325: 701-5, 1997.
170. Henderson WR, Klebanoff SJ. Leukotriene production and inactivation by normal, chronic granulomatous disease and myeloperoxidase-deficient neutrophils. J Biol Chem 258: 13522-27, 1983.
171. Herzing LB, Romer JT, Horn JM, Ashworth A. Xist has properties of the X-chromosome inactivation centre. Nature 386: 272-75, 1997.
172. Heyneman RA, Vercauteren RE. Activation of a NADPH oxidase from horse polymorphonuclear leukocytes in a cell-free system. J Leukoc Biol 36: 751-59, 1984.
173. Heyworth PG, Bohl BP, Bokoch GM, Curnutte JT. Rac translocates independently of the neutrophil NADPH oxidase components p47phox and p67phox. Evidence for its interaction with flavocytochrome b558. J Biol Chem 269: 30749-52, 1994.
174. Heyworth PG, Curnutte JT, Nauseef WM, Volpp BD, Pearson DW, Rosen H, Clark RA. Neutrophil nicotinamide adenine dinucleotide phosphate oxidase assembly. Translocation of p47-phox and p67-phox requires interaction between p47-phox and cytochrome b558. J Clin Invest 87: 352-56, 1991.
175. Heyworth PG, Curnutte JT, Noack D, Cross AR. Hematologically important mutations: X-linked chronic granulomatous disease - an update. Blood Cells Mol Dis 23: 443-50, 1997.
176. Heyworth PG, Shrimpton CF, Segal AW. Localization of the 47 kDa phosphoprotein involved in the respiratory-burst NADPH oxidase of phagocytic cells. Biochem J 260: 243-48, 1989.
177. Hiraoka W, Vazquez N, Nieves-Neira W, Chanock SJ, Pommier Y. Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells. J Clin Invest 102: 1961-68, 1998.
178. Ho CM, Vowels MR, Lockwood L, Ziegler JB. Successful bone marrow transplantation in a child with X-linked chronic granulomatous disease. Bone Marrow Transplant 18: 213-15, 1996.
179. Hohaus S, Petrovick MS, Voso MT, Sun Z, Zhang DE, Tenen DG. PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene. Mol Cell Biol 15: 5830-45, 1995.
180. Holland SM, Dorman SE, Kwon A, Pitha-Rowe IF, Frucht DM, Gerstberger SM, Noel GJ, Vesterhus P, Brown MR, Fleisher TA. Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency. J Infect Dis 178: 1095-104, 1998.
181. Holland SM, Eisenstein EM, Kuhns DB, Turner ML, Fleisher TA, Strober W, Gallin JI. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 330: 1348-55, 1994.
182. Holmes B, Page AR, Good RA. Studies of the metabolic activity of leukocytes from patients with a genetic abnormality of phagocytic function. J Clin Invest 46: 1422-32, 1967.
183. Hu Q, Corda S, Zweier JL, Capogrossi MC, Ziegelstein RC. Hydrogen peroxide induces intracellular calcium oscillations in human aortic endothelial cells. Circulation 97: 268-75, 1998.
184. Inanami O, Johnson JL, McAdara JK, Benna JE, Faust LR, Newburger PE, Babior BM. Activation of the leukocyte NADPH oxidase by phorbol ester requires the phosphorylation of p47PHOX on serine 303 or 304. J Biol Chem 273: 9539-43, 1998.
185. International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 324: 509-16, 1991.
186. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275: 1649-52, 1997.
187. Ito T, Nakamura R, Sumimoto H, Takeshige K, Sakaki Y. An SH3 domain-mediated interaction between the phagocyte NADPH oxidase factors p40phox and p47phox. FEBS Lett 385: 229-32, 1996.
188. Iwata M, Nunoi H, Matsuda I, Kanegasaki S, Tsuruo T, Sugimoto Y. Drug-selected complete restoration of superoxide generation in Epstein-Barr virus-transformed B cells from p47phox-deficient chronic granulomatous disease patients by using a bicistronic retrovirus vector encoding a human multi-drug resistance gene (MDR1) and the p47phox gene. Hum Genet 103: 419-23, 1998.
189. Iwata M, Nunoi H, Yamazaki H, Nakano T, Niwa H, Tsuruta S, Ohga S, Ohmi S, Kanegasaki S, Matsuda I. Homologous dinucleotide (GT or TG) deletion in Japanese patients with chronic granulomatous disease with p47-phox deficiency. Biochem Biophys Res Commun 199: 1372-77, 1994.
190. Iyer GYN, Quastel JH. NADPH and NADH oxidation by guinea pig polymorphonuclear leucocytes. Can J Biochem Physiol 41: 427, 1963.
191. Iyer SS, Pearson DW, Nauseef WM, Clark RA. Evidence for a readily dissociable complex of p47phox and p67phox in cytosol of unstimulated human neutrophils. J Biol Chem 269: 22405-11, 1994.
192. Jackson SH, Gallin JI, Holland SM. The p47phox mouse knock-out model of chronic granulomatous disease. J Exp Med 182: 751-58, 1995.
193. Johnson JL, Park JW, Benna JE, Faust LP, Inanami O, Babior BM. Activation of p47phox, a cytosolic subunit of the leukocyte NADPH oxidase. Phosphorylation of ser-359 or ser-370 precedes phosphorylation at other sites and is required for activity. J Biol Chem 273: 35147-52, 1998.
194. Johnston HC, Shigeoka AO, Hurley DC, Pysher TJ. Nocardia pneumonia in a neonate with chronic granulomatous disease. Pediatr Infect Dis J 8: 526-28, 1989.
195. Johnston RB III, Harbeck RJ, Johnston RB Jr. Recurrent severe infections in a girl with apparently variable expression of mosaicism for chronic granulomatous disease. J Pediatr 106: 50-55, 1985.
196. Jones SA, Hancock JT, Jones OT, Neubauer A, Topley N. The expression of NADPH oxidase components in human glomerular mesangial cells: Detection of protein and mRNA for p47phox, p67phox, and p22phox. J Am Soc Nephrol 5: 1483-91, 1995.
197. Joneson T, Bar-Sagi D. A Rac1 effector site controlling mitogenesis through superoxide production. J Biol Chem 273: 17991-94, 1998.
198. Jonsson S, Wallace RJ Jr, Hull SI, Musher DM. Recurrent Nocardia pneumonia in an adult with chronic granulomatous disease. Am Rev Respir Dis 133: 932-34, 1986.
199. Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile JF, Newport M, Levin M, Blanche S, Seboun E, Fischer A, Casanova JL. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 335: 1956-61, 1996.
200. Kamani N, August CS, Campbell DE, Hassan NF, Douglas SD. Marrow transplantation in chronic granulomatous disease: An update, with 6-year follow-up. J Pediatr 113: 697-700, 1988.
201. Kamani N, August CS, Douglas SD, Burkey E, Etzioni A, Lischner HW. Bone marrow transplantation in chronic granulomatous disease. J Pediatr 105: 42-46, 1984.
202. Kang CD, Jang JH, Kim KW, Lee HJ, Jeong CS, Kim CM, Kim SH, Chung BS. Activation of c-jun N-terminal kinase/stress-activated protein kinase and the decreased ratio of Bcl-2 to Bax are associated with the auto-oxidized dopamine-induced apoptosis in PC12 cells. Neurosci Lett 256: 37-40, 1998.
203. Kaplan EL, Laxdal T, Quie PG. Studies of polymorphonuclear leukocytes from patients with chronic granulomatous disease of childhood: Bactericidal capacity for streptococci. Pediatrics 41: 591-99, 1968.
204. Kaplan SS, Finn R, Kusne S, Rae J, Curnutte J. Morbid infection in a chronic granulomatous disease carrier [abstract]. Blood 92(Suppl. 1): 46B, 1998.
205. Kenney RT, Kwon-Chung KJ, Waytes AT, Melnick DA, Pass HI, Merino MJ, Gallin JI. Successful treatment of systemic Exophiala dermatitidis infection in a patient with chronic granulomatous disease. Clin Infect Dis 14: 235-42, 1992.
206. Kenney RT, Kwon-Chung KJ, Witebsky FG, Melnick DA, Malech HL, Gallin JI. Invasive infection with Sarcinosporon inkin in a patient with chronic granulomatous disease. Am J Clin Pathol 94: 344-50, 1990.
207. Kenney RT, Malech HL, Epstein ND, Roberts RL, Leto TL. Characterization of the p67phox gene: Genomic organization and restriction fragment length polymorphism analysis for prenatal diagnosis in chronic granulomatous disease. Blood 82: 3739-44, 1993.
208. Kim M, Shin JH, Suh SP, Ryang DW, Park CS, Kim C, Kook H, Kim J. Aspergillus nidulans infection in a patient with chronic granulomatous disease. J Korean Med Sci 12: 244-48, 1997.
209. Kjeldsen L, Sengelov H, Lollike K, Nielsen MH, Borregaard N. Isolation and characterization of gelatinase granules from human neutrophils. Blood 83: 1640-49, 1994.
210. Klebanoff SJ. Iodination of bacteria: A bactericidal mechanism. J Exp Med 126: 1063-78, 1967.
211. Klebanoff SJ. Reactive nitrogen intermediates and antimicrobial activity: Role of nitrite. Free Radic Biol Med 14: 351-60, 1993.
212. Klebanoff SJ. Role of the superoxide anion in the myeloperoxidase-mediated antimicrobial system. J Biol Chem 249: 3724-28, 1974.
213. Klebanoff SJ, Nathan CF. Nitrite production by stimulated human polymorphonuclear leukocytes supplemented with azide and catalase. Biochem Biophys Res Commun 197: 192-96, 1993.
214. Klebanoff SJ, White LR. Iodination defect in the leukocytes of a patient with chronic granulomatous disease of childhood. N Engl J Med 280: 460-66, 1969.
215. Kleinberg ME, Malech HL, Rotrosen D. The phagocyte 47-kilodalton cytosolic oxidase protein is an early reactant in activation of the respiratory burst. J Biol Chem 265: 15577-83, 1990.
216. Kleinberg ME, Mital D, Rotrosen D, Malech HL. Characterization of a phagocyte cytochrome b558 91-kilodalton subunit functional domain: Identification of peptide sequence and amino acids essential for activity. Biochemistry 31: 2686-90, 1992.
217. Knaus UG, Heyworth PG, Evans T, Curnutte JT, Bokoch GM. Regulation of phagocyte oxygen radical production by the GTP-binding protein Rac 2. Science 254: 1512-15, 1991.
218. Knaus UG, Heyworth PG, Kinsella BT, Curnutte JT, Bokoch GM. Purification and characterization of Rac 2. A cytosolic GTP-binding protein that regulates human neutrophil NADPH oxidase. J Biol Chem 267: 23575-82, 1992.
219. Knaus UG, Morris S, Dong HJ, Chernoff J, Bokoch GM. Regulation of human leukocyte p21-activated kinases through G protein-coupled receptors. Science 269: 221-23, 1995.
220. Kobayashi T, Robinson JM, Seguchi H. Identification of intracellular sites of superoxide production in stimulated neutrophils. J Cell Sci 111: 81-91, 1998.
221. Kohno T, Yamada Y, Hata T, Mori H, Yamamura M, Tomonaga M, Urata Y, Goto S, Kondo T. Relation of oxidative stress and glutathione synthesis to CD95(Fas/APO-1)-mediated apoptosis of adult T cell leukemia cells. J Immunol 156: 4722-28, 1996.
222. Koshkin V, Pick E. Generation of superoxide by purified and relipidated cytochrome b559 in the absence of cytosolic activators. FEBS Lett 327: 57-62, 1993.
223. Koshkin V, Pick E. Superoxide production by cytochrome b559. Mechanism of cytosol-independent activation. FEBS Lett 338: 285-89, 1994.
224. Kubo H, Morgenstern D, Quinian WM, Ward PA, Dinauer MC, Doerschuk CM. Preservation of complement-induced lung injury in mice with deficiency of NADPH oxidase. J Clin Invest 97: 2680-84, 1996.
225. Kuribayashi F, Kumatori A, Suzuki S, Nakamura M, Matsumoto T, Tsuji Y. Human peripheral eosinophils have a specific mechanism to express gp91-phox, the large subunit of cytochrome b558. Biochem Biophys Res Commun 209: 146-52, 1995.
226. Kwong CH, Adams AG, Leto TL. Characterization of the effector-specifying domain of Rac involved in NADPH oxidase activation. J Biol Chem 270: 19868-72, 1995.
227. Landing BH, Shirkey HS. Syndrome of recurrent infection and infiltration of viscera by pigmented lipoid histiocytes. Pediatrics 20: 431-38, 1957.
228. Lau YL, Chan GC, Ha SY, Hui YF, Yuen KY. The role of phagocytic respiratory burst in host defense against Mycobacterium tuberculosis. Clin Infect Dis 26: 226-27, 1998.
229. Lazarus GM, Neu HC. Agents responsible for infection in chronic granulomatous disease of childhood. J Pediatr 86: 415-17, 1975.
230. Lee BW, Yap HK. Polyarthritis resembling juvenile rheumatoid arthritis in a girl with chronic granulomatous disease. Arthritis Rheum 37: 773-76, 1994.
231. Lekstrom-Himes JA, Holland SM, DeCarlo ES, Miller J, Leitman SF, Chang R, Baker AR, Gallin JI. Treatment with intralesional granulocyte instillations and interferon-gamma for a patient with chronic granulomatous disease and multiple hepatic abscesses. Clin Infect Dis 19: 770-73, 1994.
232. Leonard WJ, Noguchi M, Russell SM, McBride OW. The molecular basis of X-linked severe combined immunodeficiency: The role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c. Immunol Rev 138: 61-86, 1994.
233. Leto TL. The respiratory oxidase. In: Gallin JI, Snyderman R, eds. Inflammation: Basic principles and clinical correlates. Vol. 1. Philadelphia: Lippincott Williams & Wilkins, pp 769-86, 1999.
234. Leto TL, Adams AG, de Mendez I. Assembly of the phagocyte NADPH oxidase: Binding of Src homology 3 domains to proline-rich targets. Proc Natl Acad Sci U S A 91: 10650-54, 1994.
235. Leto TL, Lomax KJ, Volpp BD, Nunoi H, Sechler JM, Nauseef WM, Clark RA, Gallin JI, Malech HL. Cloning of a 67-kD neutrophil oxidase factor with similarity to a noncatalytic region of p60c-src. Science 248: 727-30, 1990.
236. Leusen JH, Bolscher BG, Hilarius PM, Weening RS, Kaulfersch W, Seger RA, Roos D, Verhoeven AJ. 156Pro→Gln substitution in the light chain of cytochrome b558 of the human NADPH oxidase (p22-phox) leads to defective translocation of the cytosolic proteins p47-phox and p67-phox. J Exp Med 180: 2329-34, 1994.
237. Leusen JH, de Boer M, Bolscher BG, Hilarius PM, Weening RS, Ochs HD, Roos D, Verhoeven AJ. A point mutation in gp91-phox of cytochrome b558 of the human NADPH oxidase leading to defective translocation of the cytosolic proteins p47-phox and p67-phox. J Clin Invest 93: 2120-26, 1994.
238. Leusen JH, de Klein A, Hilarius PM, Ahlin A, Palmblad J, Smith CI, Diekmann D, Hall A, Verhoeven AJ, Roos D. Disturbed interaction of p21-rac with mutated p67-phox causes chronic granulomatous disease. J Exp Med 184: 1243-49, 1996.
239. Lew PD, Southwick FS, Stossel TP, Whitin JC, Simons E, Cohen HJ. A variant of chronic granulomatous disease: Deficient oxidative metabolism due to a low-affinity NADPH oxidase. N Engl J Med 305: 1329-33, 1981.
240. Li F, Linton GF, Sekhsaria S, Whiting-Theobald N, Katkin JP, Gallin JI, Malech HL. CD34+ peripheral blood progenitors as a target for genetic correction of the two flavocytochrome b558 defective forms of chronic granulomatous disease. Blood 84: 53-68, 1994.
241. Li LL, Dinauer MC. Reconstitution of NADPH oxidase activity in human X-linked chronic granulomatous disease myeloid cells after stable gene transfer using a recombinant adeno-associated virus 2 vector. Blood Cells Mol Dis 24: 522-38, 1998.
242. Li PF, Dietz R, von Harsdorf R. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation 96: 3602-9, 1997.
243. Li SL, Valente AJ, Zhao SJ, Clark RA. PU.1 is essential for p47phox promoter activity in myeloid cells. J Biol Chem 272: 17802-9, 1997.
244. Liese JG, Jendrossek V, Jansson A, Petropoulou T, Kloos S, Gahr M, Belohradsky BH. Chronic granulomatous disease in adults. Lancet 347: 220-23, 1996.
245. Lindskov R, Munkvad JM, Valerius NH. Discoid lupus erythematosus and carrier status of X-linked chronic granulomatous disease. Dermatologica 167: 231-33, 1983.
246. Lomax KJ, Leto TL, Nunoi H, Gallin JI, Malech HL. Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease. Science 245: 409-12, 1989.
247. Lovas JG, Issekutz A, Walsh N, Miller RA. Lupus erythematosus-like oral mucosal and skin lesions in a carrier of chronic granulomatous disease. Chronic granulomatous disease carrier genodermatosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 80: 78-82, 1995.
248. Luo W, Skalnik DG. CCAAT displacement protein competes with multiple transcriptional activators for binding to four sites in the proximal gp91phox promoter. J Biol Chem 271: 18203-10, 1996.
249. Lyon MF. Evolution of X-chromosome inactivation in mammals. Nature 250: 651-53, 1974.
250. M'Rabet L, Coffer P, Zwartkruis F, Franke B, Segal AW, Koenderman L, Bos JL. Activation of the small GTPase rap1 in human neutrophils. Blood 92: 2133-40, 1998.
251. Macher AM, Casale TB, Fauci AS. Chronic granulomatous disease of childhood and Chromobacterium violaceum infections in the south-eastern United States. Ann Intern Med 97: 51-55, 1982.
252. Macher AM, Casale TB, Gallin JI, Boltansky H, Fauci AS. Chromobacterium violaceum infectious and chronic granulomatous disease [letter]. Ann Intern Med 98: 259, 1983.
253. Malech HL, Bauer TR Jr, Hickstein DD. Prospects for gene therapy of neutrophil defects. Semin Hematol 34: 355-61, 1997.
254. Malech HL, Maples PB, Whiting-Theobald N, Linton GF, Sekhsaria S, Vowells SJ, Li F, Miller JA, DeCarlo E, Holland SM, Leitman SF, Carter CS, Butz RE, Read EJ, Fleisher TA, Schneiderman RD, Van Epps DE, Spratt SK, Maack CA, Rokovich JA, Cohen LK, Gallin JI. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 94: 12133-38, 1997.
255. Maly FE, Schuerer-Maly CC, Quilliam L, Cochrane CG, Newburger PE, Curnutte JT, Gifford M, Dinauer MC. Restitution of superoxide generation in autosomal cytochrome-negative chronic granulomatous disease (A22(0) CGD)-derived B lymphocyte cell lines by transfection with p22phax cDNA. J Exp Med 178: 2047-53, 1993.
256. Manzi S, Urbach AH, McCune AB, Altman HA, Kaplan SS, Medsger TA Jr, Ramsey-Goldman R. Systemic lupus erythematosus in a boy with chronic granulomatous disease: Case report and review of the literature. Arthritis Rheum 34: 101-5, 1991.
257. Mardiney M III, Jackson SH, Spratt SK, Li F, Holland SM, Malech HL. Enhanced host defense after gene transfer in the murine p47phox-deficient model of chronic granulomatous disease. Blood 89: 2268-75, 1997.
258. Margolis DM, Melnick DA, Alling DW, Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 162: 723-26, 1990.
259. Marshall C, Mamary AJ, Verhoeven AJ, Marshall BE. Pulmonary artery NADPH-oxidase is activated in hypoxic pulmonary vasoconstriction. Am J Respir Cell Mol Biol 15: 633-44, 1996.
260. McKusick VA. Mendelian inheritance in man: A catalog of human genes and genetic disorders. 12th ed. Baltimore: Johns Hopkins University Press, 1998.
261. McPhail LC, Qualliotine-Mann D, Waite KA. Cell-free activation of neutrophil NADPH oxidase by a phosphatidic acid-regulated protein kinase. Proc Natl Acad Sci U S A 92: 7931-35, 1995.
262. McPhail LC, Shirley PS, Clayton CC, Snyderman R. Activation of the respiratory burst enzyme from human neutrophils in a cell-free system. Evidence for a soluble cofactor. J Clin Invest 75: 1735-39, 1985.
263. McRipley RJ, Sbarra AJ. Role of the phagocyte in host-parasite interactions. XII. Hydrogen peroxide-myeloperoxidase bactericidal system in the phagocyte. J Bacteriol 94: 1425-30, 1967.
264. Meischl C, Roos D. The molecular basis of chronic granulomatous disease. Springer Semin Immunopathol 19: 417-34, 1998.
265. Milligan SA, Owens MW, Grisham MB. Differential regulation of extracellular signal-regulated kinase and nuclear factor-kappa B signal transduction pathways by hydrogen peroxide and tumor necrosis factor. Arch Biochem Biophys 352: 255-62, 1998.
266. Mizuki K, Kadomatsu K, Hata K, Ito T, Fan QW, Kage Y, Fukumaki Y, Sakaki Y, Takeshige K, Sumimoto H. Functional modules and expression of mouse p40phox and p67phox, SH3-domain-containing proteins involved in the phagocyte NADPH oxidase complex. Eur J Biochem 251: 573-82, 1998.
267. Morgenstern DE, Gifford MA, Li LL, Doerschuk CM, Dinauer MC. Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus. J Exp Med 185: 207-18, 1997.
268. Monta Y, Clemens MG, Miller LS, Rangan LI, Kondo S, Miyasaka M, Yoshikawa T, Bulkley GB. Reactive oxidants mediate TNF-alpha-induced leukocyte adhesion to rat mesenteric venular endothelium. Am J Physiol 269: H1833-42, 1995.
269. Mouy R, Fischer A, Vilmer E, Seger R, Griscelli C. Incidence, severity, and prevention of infections in chronic granulomatous disease. J Pediatr 114: 555-60, 1989.
270. Mouy R, Veber F, Blanche S, Donadieu J, Brauner R, Levron JC, Griscelli C, Fischer A. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr 125: 998-1003, 1994.
271. Muhlebach TJ, Gabay J, Nathan CF, Erny C, Dopfer G, Schroten H, Wahn V, Seger RA. Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma does not improve neutrophil oxidative metabolism, cytochrome b558 content or levels of four anti-microbial proteins. Clin Exp Immunol 88: 203-6, 1992.
272. Muhlebach TJ, Robinson W, Seger RA, Machler M. A second NsiI RFLP at the CYBB locus. Nucleic Acids Res 18: 4966, 1990.
273. Murray HW, Spitalny GL, Nathan CF. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J Immunol 134: 1619-22, 1985.
274. Naccache PH, Gilbert C, Caon AC, Gaudry M, Huang CK, Bonak VA, Umezawa K, McColl SR. Selective inhibition of human neutrophil functional responsiveness by erbstatin, an inhibitor of tyrosine protein kinase. Blood 76: 2098-104, 1990.
275. Nakamura R, Sumimoto H, Mizuki K, Hata K, Ago T, Kitajima S, Takeshige K, Sakaki Y, Ito T. The PC motif: A novel and evolutionarily conserved sequence involved in interaction between p40phox and p67phox, SH3 domain-containing cytosolic factors of the phagocyte NADPH oxidase. Eur J Biochem 251: 583-89, 1998.
276. Nakanishi A, Imajoh-Ohmi S, Fujinawa T, Kikuchi H, Kanegasaki S. Direct evidence for interaction between COOH-terminal regions of cytochrome b558 subunits and cytosolic 47-kDa protein during activation of an O(2-)-generating system in neutrophils. J Biol Chem 267: 19072-74, 1992.
277. Nathan CF, Horowitz CR, de la Harpe J, Vadhan-Raj S, Sherwin SA, Oettgen HF, Krown SE. Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci U S A 82: 8686-90, 1985.
278. Nathan CF, Kaplan G, Levis WR, Nusrat A, Witmer MD, Sherwin SA, Job CK, Horowitz CR, Steinman RM, Cohn ZA. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med 315: 6-15, 1986.
279. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 158: 670-89, 1983.
280. Nauseef WM, McCormick S, Renee J, Leidal KG, Clark RA. Functional domain in an arginine-rich carboxyl-terminal region of p47phox. J Biol Chem 268: 23646-51, 1993.
281. Nauseef WM, Volpp BD, McCormick S, Leidal KG, Clark RA. Assembly of the neutrophil respiratory burst oxidase. Protein kinase C promotes cytoskeletal and membrane association of cytosolic oxidase components. J Biol Chem 266: 5911-17, 1991.
282. Neijens HJ, Frenkel J, de Muinck Keizer-Schrama SM, Dzoljic-Danilovic G, Meradji M, van Dongen JJ. Invasive Aspergillus infection in chronic granulomatous disease: Treatment with itraconazole. J Pediatr 115: 1016-19, 1989.
283. Newburger PE, Cohen HJ, Rothchild SB, Hobbins JC, Malawista SE, Mahoney MJ. Prenatal diagnosis of chronic granulomatous disease. N Engl J Med 300: 178-81, 1979.
284. Newburger PE, Dai Q, Whitney C. In vitro regulation of human phagocyte cytochrome b heavy and light chain gene expression by bacterial lipopolysaccharide and recombinant human cytokines. J Biol Chem 266: 16171-77, 1991.
285. Newburger PE, Luscinskas FW, Ryan T, Beard CJ, Wright J, Platt OS, Simons ER, Tauber AI. Variant chronic granulomatous disease: Modulation of the neutrophil defect by severe infection. Blood 68: 914-19, 1986.
286. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, Levin M. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 335: 1941-49, 1996.
287. Nisen PD, Waber PG. Nonrandom X chromosome DNA methylation patterns in hemophiliac females. J Clin Invest 83: 1400-3, 1989.
288. Nisimoto Y, Freeman JLR, Motalebi SA, Hirshberg M, Lambeth JD. Rac binding to p67phox. Structural basis for interactions of the Rac1 effector region and insert region with components of the respiratory burst oxidase. J Biol Chem 272: 18834-41, 1997.
289. Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73: 147-57, 1993.
290. Nunoi H, Rotrosen D, Gallin JT, Malech HL. Two forms of autosomal chronic granulomatous disease lack distinct neutrophil cytosol factors. Science 242: 1298-301, 1988.
291. Oelgeschlager M, Nuchprayoon I, Luscher B, Friedman AD. C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter. Mol Cell Biol 16: 4717-25, 1996.
292. Ohga S, Ikeuchi K, Kadoya R, Okada K, Miyazaki C, Suita S, Ueda K. Intrapulmonary Mycobacterium avium infection as the first manifestation of chronic granulomatous disease. J Infect 34: 147-50, 1997.
293. Ohno Y, Gallin JI. Diffusion of extracellular hydrogen peroxide into intracellular compartments of human neutrophils. Studies utilizing the inactivation of myeloperoxidase by hydrogen peroxide and azide. J Biol Chem 260: 8438-46, 1985.
294. Ortiz-Romero PL, Corell-Alniuzara A, Lopez-Estebaranz JL, Arranz FR, Ruiz-Contreras J. Lupus like lesions in a patient with X-linked chronic granulomatous disease and recombinant X chromosome. Dermatology 195: 280-83, 1997.
295. Ozsahin H, von Planta M, Muller I, Steinert HC, Nadal D, Lauener R, Tuchschmid P, Willi UV, Ozsahin M, Crompton NE, Seger RA. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 92: 2719-24, 1998.
296. Pacelli R, Wink DA, Cook JA, Krishna MC, DeGraff W, Friedman N, Tsokos M, Samuni A, Mitchell JB. Nitric oxide potentiates hydrogen peroxide-induced killing of Escherichia coli. J Exp Med 182: 1469-79, 1995.
297. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: Enhancement by angiotensin II. Proc Natl Acad Sci U S A 94: 14483-88, 1997.
298. Pagano PJ, Ito Y, Tornheim K, Gallop PM, Tauber AI, Cohen RA. An NADPH oxidase superoxide-generating system in the rabbit aorta. Am J Physiol 268: H2274-80, 1995.
299. Pahl HL, Scheibe RJ, Zhang DE, Chen HM, Galson DL, Maki RA, Tenen DG. The proto-oncogene PU.1 regulates expression of the myeloid-specific CD11b promoter. J Biol Chem 268: 5014-20, 1993.
300. Park JW. Phosphatidic acid-induced translocation of cytosolic components in a cell-free system of NADPH oxidase: Mechanism of activation and effect of diacylglycerol. Biochem Biophys Res Commun 229: 758-63, 1996.
301. Park JW, Babior BM. Activation of the leukocyte NADPH oxidase subunit p47phox by protein kinase C. A phosphorylation-dependent change in the conformation of the C-terminal end of p47phox. Biochemistry 36: 7474-80, 1997.
302. Parkos CA, Allen RA, Cochrane CG, Jesaitis AJ. Purified cytochrome b from human granulocyte plasma membrane is comprised of two polypeptides with relative molecular weights of 91,000 and 22,000. J Clin Invest 80: 732-42, 1987.
303. Parkos CA, Dinauer MC, Walker LE, Allen RA, Jesaitis AJ, Orkin SH. Primary structure and unique expression of the 22-kilodalton light chain of human neutrophil cytochrome b. Proc Natl Acad Sci U S A 85: 3319-23, 1988.
304. Parks DA, Granger DN, Bulkley GB, Shah AK. Soybean trypsin inhibitor attenuates ischemic injury to the feline small intestine. Gastroenterology 89: 6-12, 1985.
305. Parolini O, Ressmann G, Haas OA, Pawlowsky J, Gadner H, Knapp W, Holter W. X-linked Wiskott-Aldrich syndrome in a girl. N Engl J Med 338: 291-95, 1998.
306. Patino PJ, Perez JE, Lopez JA, Condino-Neto A, Grumach AS, Botero JH, Curnutte JT, Garcia de Olarte D. Molecular analysis of chronic granulomatous disease caused by defects in gp91-phox. Hum Mutat 13: 29-37, 1999.
307. Peddle CM, Wolf CR, McLellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 99: 625-31, 1997.
308. Pelham A, Malcolm S, Levinsky RJ, Kinnon C. An additional NsiI RFLP at the X-linked chronic granulomatous disease (CYBB) locus. Nucleic Acids Res 18: 7199, 1990.
309. Peng M, Huang L, Xie ZJ, Huang WH, Askari A. Oxidant-induced activations of nuclear factor-kappa B and activator protein-1 in cardiac myocytes. Cell Mol Biol Res 41: 189-97, 1995.
310. Penny GD, Kay GF, Sheardown SA, Rastan S, Brockdorff N. Requirement for Xist in X chromosome inactivation. Nature 379: 131-37, 1996.
311. Perez C, Coeffler E, Moreau-Gachelin F, Wietzerbin J, Benech PD. Involvement of the transcription factor PU.1/Spi-1 in myeloid cell-restricted expression of an interferon-inducible gene encoding the human high-affinity Fc gamma receptor. Mol Cell Biol 14: 5023-31, 1994.
312. Peveri P, Heyworth PG, Curnutte JT. Absolute requirement for GTP in activation of human neutrophil NADPH oxidase in a cell-free system: Role of ATP in regenerating GTP. Proc Natl Acad Sci U S A 89: 2494-98, 1992.
313. Pinkus R, Weiner LM, Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transferase gene expression. J Biol Chem 271: 13422-29, 1996.
314. Pitt J, Bernheimer HP. Role of peroxide in phagocytic killing of pneumococci. Infect Immun 9: 48-52, 1974.
315. Plenge RM, Hendrich BD, Schwartz C, Arena JF, Naumova A, Sapienza C, Winter RM, Willard HF. A promoter mutation in the XIST gene in two unrelated families with skewed X-chromosome inactivation. Nat Genet 17: 353-56, 1997.
316. Pollock JD, Williams DA, Gifford MA, Li LL, Du X, Fisherman J, Orkin SH, Doerschuk CM, Dinauer MC. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet 9: 202-9, 1995.
317. Porter CD, Parkar MH, Collins MK, Levinsky RJ, Kinnon C. Efficient retroviral transduction of human bone marrow progenitor and long-term culture-initiating cells: Partial reconstitution of cells from patients with X-linked chronic granulomatous disease by gp91-phox expression. Blood 87: 3722-30, 1996.
318. Porter CD, Parkar MH, Levinsky RJ, Collins MK, Kinnon C. X-linked chronic granulomatous disease: Correction of NADPH oxidase defect by retrovirus-mediated expression of gp91-phox. Blood 82: 2196-202, 1993.
319. Porter CD, Parkar MH, Verhoeven AJ, Levinsky RJ, Collins MK, Kinnon C. p22-phox-deficient chronic granulomatous disease: Reconstitution by retrovirus-mediated expression and identification of a biosynthetic intermediate of gp91-phox. Blood 84: 2767-75, 1994.
320. Prigmore E, Ahmed S, Best A, Kozma R, Manser E, Segal AW, Lim L. A 68-kDa kinase and NADPH oxidase component p67phox are targets for Cdc42Hs and Rac1 in neutrophils. J Biol Chem 270: 10717-22, 1995.
321. Qualliotine-Mann D, Agwu DE, Ellenburg MD, McCall CE, McPhail LC. Phosphatidic acid and diacylglycerol synergize in a cell-free system for activation of NADPH oxidase from human neutrophils. J Biol Chem 268: 23843-49, 1993.
322. Quie PG, Kaplan EL, Page AR, Gruskay FL, Malawista SE. Defective polymorphonuclear-leukocyte function and chronic granulomatous disease in two female children. N Engl J Med 278: 976-80, 1968.
323. Quie PG, White JG, Holmes B, Good RA. In vitro bactericidal capacity of human polymorphonuclear leukocytes: Diminished activity in chronic granulomatous disease of childhood. J Clin Invest 46: 668-79, 1967.
324. Quinn MT, Parkos CA, Walker L, Orkin SH, Dinauer MC, Jesaitis AJ. Association of a Ras-related protein with cytochrome b of human neutrophils. Nature 342: 198-200, 1989.
325. Rae J, Newburger PE, Dinauer MC, Noack D, Hopkins PJ, Kuruto R, Curnutte JT. X-Linked chronic granulomatous disease: Mutations in the CYBB gene encoding the gp91-phox component of respiratory-burst oxidase. Am J Hum Genet 62:
326. Rex JH, Bennett JE, Gallin JI, Malech HL, Melnick DA. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis 162: 523-28, 1990.
327. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther 80: 35-47, 1998.
328. Roberts AW, Kim C, Zhen L, Lowe JB, Kapur R, Petryniak B, Spaetti A, Pollock JD, Borneo JB, Bradford GB, Atkinson SJ, Dinauer MC, Williams DA. Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense. Immunity 10: 183-96, 1999.
329. Roesler J, Heyden S, Burdelski M, Schafer H, Kreth HW, Lehmann R, Paul D, Marzahn J, Gahr M, Rosen-Wolff A. Uncommon missense and splice mutations and resulting biochemical phenotypes in German patients with X-linked chronic granulomatous disease. Exp Hematol 27: 505-11, 1999.
330. Roos D. X-CGDbase: A database of X-CGD-causing mutations. Immunol Today 17: 517-21, 1996.
331. Roos D, de Boer M, Borregard N, Bjerrum OW, Valerius NH, Seger RA, Muhlebach T, Belohradsky BH, Weening RS. Chronic granulomatous disease with partial deficiency of cytochrome b558 and incomplete respiratory burst: Variants of the X-linked, cytochrome b558-negative form of the disease. J Leukoc Biol 51: 164-71, 1992.
332. Roos D, de Boer M, Kuribayashi F, Meischl C, Weening RS, Segal AW, Ahlin A, Nemet K, Hossle JP, Bernatowska-Matuszkiewicz E, Middle-ton-Price H. Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood 87: 1663-81, 1996.
333. Rosh JR, Tang HB, Mayer L, Groisman G, Abraham SK, Prince A. Treatment of intractable gastrointestinal manifestations of chronic granulomatous disease with cyclosporine. J Pediatr 126: 143-45, 1995.
334. Rosmarin AG, Caprio D, Levy R, Simkevich C. CD18 (beta 2 leukocyte integrin) promoter requires PU.1 transcription factor for myeloid activity. Proc Natl Acad Sci U S A 92: 801-5, 1995.
335. Ross JP, Holland SM, Gill VJ, DeCarlo ES, Gallin JI. Severe Burkholderia (Pseudomonas) gladioli infection in chronic granulomatous disease: Report of two successfully treated cases. Clin Infect Dis 21: 1291-93, 1995.
336. Rossi F, Zatti M. Biochemical aspects of phagocytosis in polymorphonuclear leucocytes: NADH and NADPH oxidation by the granules of resting and phagocytosing cells. Experientia 20: 21-23, 1964.
337. Rossi F, Zatti M. Mechanism of the respiratory stimulation in saponine-treated leucocytes. The KCN-insensitive oxidation of NADPH. Biochim Biophys Acta 153: 296-99, 1968.
338. Rotrosen D, Kleinberg ME, Nunoi H, Leto T, Gallin JI, Malech HL. Evidence for a functional cytoplasmic domain of phagocyte oxidase cytochrome b558. J Biol Chem 265: 8745-50, 1990.
339. Rotrosen D, Leto TL. Phosphorylation of neutrophil 47-kDa cytosolic oxidase factor. Translocation to membrane is associated with distinct phosphorylation events. J Biol Chem 265: 19910-15, 1990.
340. Rotrosen D, Yeung CL, Leto TL, Malech HL, Kwong CH. Cytochrome b558: The flavin-binding component of the phagocyte NADPH oxidase. Science 256: 1459-62, 1992.
341. Royer-Pokora B, Kunkel LM, Monaco AP, Goff SC, Newburger PE, Baehner RL, Cole FS, Curnutte JT, Orkin SH. Cloning the gene for the inherited disorder chronic granulomatous disease on the basis of its chromosomal location. Cold Spring Harb Symp Quant Biol 51: 177-83, 1986.
342. Rusyn I, Tsukamoto H, Thurman RG. WY-14 643 rapidly activates nuclear factor kappaB in Kupffer cells before hepatocytes. Carcinogenesis 19: 1217-22, 1998.
343. Sadat MA, Kumatori A, Suzuki S, Yamaguchi Y, Tsuji Y, Nakamura M. GATA-3 represses gp91phox gene expression in eosinophil-committed HL-60-C15 cells. FEBS Lett 436: 390-94, 1998.
344. Sandstrom PA, Mannie MD, Buttke TM. Inhibition of activation-induced death in T cell hybridomas by thiol antioxidants: Oxidative stress as a mediator of apoptosis. J Leukoc Biol 55: 221-26, 1994.
345. Saraste M. Location of haem-binding sites in the mitochondrial cytochrome b. FEBS Lett 166: 367-72, 1984.
346. Sathyamoorthy M, de Mendez I, Adams AG, Leto TL. p40phox down-regulates NADPH oxidase activity through interactions with its SH3 domain. J Biol Chem 272: 9141-46, 1997.
347. Sbarra AJ, Karnovsky ML. The biochemical basis of phagocytosis. 1. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes. J Biol Chem 234: 1355-62, 1959.
348. Schiff DE, Rae J, Martin TR, Davis BH, Curnutte JT. Increased phagocyte Fc gammaRI expression and improved Fc gamma-receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood 90: 3187-94, 1997.
349. Schmidt KN, Amstad P, Cerutti P, Baeuerle PA. Identification of hydrogen peroxide as the relevant messenger in the activation pathway of transcription factor NF-kappaB. Adv Exp Med Biol 387: 63-68, 1996.
350. Schmitt CP, Scharer K, Waldherr R, Seger RA, Debatin KM. Glomerulonephritis associated with chronic granulomatous disease and systemic lupus erythematosus. Nephrol Dial Transplant 10: 891-95, 1995.
351. Sechler JM, Malech HL, White CJ, Gallin JI. Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc Natl Acad Sci U S A 85: 4874-78, 1988.
352. Segal AW. Absence of both cytochrome b-245 subunits from neutrophils in X-linked chronic granulomatous disease. Nature 326: 88-91, 1987.
353. Segal AW, Cross AR, Garcia RC, Borregaard N, Valerius NH, Soothill JF, Jones OT. Absence of cytochrome b-245 in chronic granulomatous disease. A multicenter European evaluation of its incidence and relevance. N Engl J Med 308: 245-51, 1983.
354. Segal AW, Heyworth PG, Cockcroft S, Barrowman MM. Stimulated neutrophils from patients with autosomal recessive chronic granulomatous disease fail to phosphorylate a Mr-44,000 protein. Nature 316: 547-49, 1985.
355. Segal AW, Jones OT, Webster D, Allison AC. Absence of a newly described cytochrome b from neutrophils of patients with chronic granulomatous disease. Lancet 2: 446-49, 1978.
356. Segal AW, Jones OTG. Novel cytochrome b system in phagocytic vacuoles of human granulocytes. Nature 276: 515-17, 1978.
357. Segal AW, West I, Wientjes F, Nugent JH, Chavan AJ, Haley B, Garcia RC, Rosen H, Scrace G. Cytochrome b-245 is a flavocytochrome containing FAD and the NADPH-binding site of the microbicidal oxidase of phagocytes. Biochem J 284: 781-88, 1992.
358. Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 77: 345-54, 1998.
359. Segal BH, Doherty TM, Wynn TA, Cheever AW, Sher A, Holland SM. The p47(phox-/-) mouse model of chronic granulomatous disease has normal granuloma formation and cytokine responses to Mycobacterium avium and Schistosoma mansoni eggs. Infect Immun 67: 1659-65, 1999.
360. Seger R, Steinmann B. Prenatal diagnosis of chronic granulomatous disease: Unreliability of fibroblast nitroblue tetrazolium test [letter]. Lancet 1: 1216, 1981.
361. Seger RA, Ezekowitz RA. Treatment of chronic granulomatous disease. Immunodeficiency 5: 113-30, 1994.
362. Seger RA, Tiefenauer L, Matsunaga T, Wildfeuer A, Newburger PE. Chronic granulomatous disease due to granulocytes with abnormal NADPH oxidase activity and deficient cytochrome-b. Blood 61: 423-28, 1983.
363. Seifert R, Rosenthal W, Schultz G. Guanine nucleotides stimulate NADPH oxidase in membranes of human neutrophils. FEBS Lett 205: 161-65, 1986.
364. Sekhsaria S, Gallin JI, Linton GF, Mallory RM, Mulligan RC, Malech HL. Peripheral blood progenitors as a target for genetic correction of p47phox-deficient chronic granulomatous disease. Proc Natl Acad Sci U S A 90: 7446-50, 1993.
365. Seligmann BE, Gallin JI. Use of lipophilic probes of membrane potential to assess human neutrophil activation. Abnormality in chronic granulomatous disease. J Clin Invest 66: 493-503, 1980.
366. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. Faseb J 10: 709-20, 1996.
367. Sen CK, Roy S, Packer L. Involvement of intracellular Ca2+ in oxidant-induced NF-kappa B activation. FEBS Lett 385: 58-62, 1996.
368. Senisterra GA, van Gorkom LC, Epand RM. Calcium-independent activation of protein kinase C by the dianionic form of phosphatidic acid. Biochem Biophys Res Commun 190: 33-36, 1993.
369. Sharf R, Meraro D, Azriel A, Thornton AM, Ozato K, Petricoin EF, Lamer AC, Schaper F, Hauser H, Levi BZ. Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact with interferon regulatory factors and to bind DNA. J Biol Chem 272: 9785-92, 1997.
370. Shi J, Ross CR, Leto TL, Blecha F. PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox. Proc Natl Acad Sci U S A 93: 6014-18, 1996.
371. Shiloh MU, MacMicking JD, Nicholson S, Brause JE, Potter S, Marino M, Fang F, Dinauer M, Nathan C. Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. Immunity 10: 29-38, 1999.
372. Siems WG, Capuozzo E, Verginelli D, Salerno C, Crifo C, Grune T. Inhibition of NADPH oxidase-mediated superoxide radical formation in PMA-stimulated human neutrophils by 4-hydroxynonenal - binding to -SH and -NH2 groups. Free Radic Res 27: 353-58, 1997.
373. Sillevis Smitt JH, Bos JD, Weening RS, Krieg SR. Discoid lupus erythematosus-like skin changes in patients with autosomal recessive chronic granulomatous disease [letter]. Arch Dermatol 126: 1656-58, 1990.
374. Sillevis Smitt JH, Leusen JH, Stas HG, Teeuw AH, Weening RS. Chronic bullous disease of childhood and a paecilomyces lung infection in chronic granulomatous disease. Arch Dis Child 77: 150-52, 1997.
375. Skalnik DG, Strauss EC, Orkin SH. CCAAT displacement protein as a repressor of the myelomonocytic-specific gp91-phox gene promoter. J Biol Chem 266: 16736-44, 1991.
376. Smith LT, Hohaus S, Gonzalez DA, Dziennis SE, Tenen DG. PU.1 (Spi1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood 88: 1234-47, 1996.
377. Smith RM, Connor JA, Chen LM, Babior BM. The cytosolic subunit p67phox contains an NADPH-binding site that participates in catalysis by the leukocyte NADPH oxidase. J Clin Invest 98: 977-83, 1996.
378. Sokolic RA, Sekhsaria S, Sugimoto Y, Whiting-Theobald N, Linton GF, Li F, Gottesman MM, Malech HL. A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression. Blood 87: 42-50, 1996.
379. Someya A, Nagaoka I, Yamashita T. Purification of the 260 kDa cytosolic complex involved in the superoxide production of guinea pig neutrophils. FEBS Lett 330: 215-18, 1993.
380. Sorensen RU, Jacobs MR, Shurin SB. Chromobacterium violaceum adenitis acquired in the northern United States as a complication of chronic granulomatous disease. Pediatr Infect Dis 4: 701-2, 1985.
381. Speert DP, Bond M, Woodman RC, Curnutte JT. Infection with Pseudomonas cepacia in chronic granulomatous disease: Role of nonoxidative killing by neutrophils in host defense. J Infect Dis 170: 1524-31, 1994.
382. Sponseller PD, Malech HL, McCarthy EF Jr, Horowitz SF, Jaffe G, Gallin JI. Skeletal involvement in children who have chronic granulomatous disease. J Bone Joint Surg [Am] 73: 37-51, 1991.
383. Sprong RC, Aarsman CJ, van Oirschot JF, van Asbeck BS. Dimethylthiourea protects rats against gram-negative sepsis and decreases tumor necrosis factor and nuclear factor kappaB activity. J Lab Clin Med 129: 470-81, 1997.
384. Sprong RC, Winkelhuyzen-Janssen AM, Aarsman CJ, van Oirschot JF, van der Bruggen T, van Asbeck BS. Low-dose N-acetylcysteine protects rats against endotoxin-mediated oxidative stress, but high-dose increases mortality. Am J Respir Crit Care Med 157: 1283-93, 1998.
385. Stalder JF, Dreno B, Bureau B, Hakim J. Discoid lupus erythematosus-like lesions in an autosomal form of chronic granulomatous disease. Br J Dermatol 114: 251-54, 1986.
386. Strate M, Brandrup F, Wang P. Discoid lupus erythematosus-like skin lesions in a patient with autosomal recessive chronic granulomatous disease. Clin Genet 30: 184-90, 1986.
387. Styrt B, Klempner MS. Late-presenting variant of chronic granulomatous disease. Pediatr Infect Dis 3: 556-59, 1984.
388. Sumimoto H, Kage Y, Nunoi H, Sasaki H, Nose T, Fukumaki Y, Ohno M, Minakami S, Takeshige K. Role of Src homology 3 domains in assembly and activation of the phagocyte NADPH oxidase. Proc Natl Acad Sci U S A 91: 5345-49, 1994.
389. Sun Y, Oberley LW. Redox regulation of transcriptional activators. Free Radic Biol Med 21: 335-48, 1996.
390. Suzuki K, Nakamura M, Hatanaka Y, Kayanoki Y, Tatsumi H, Taniguchi N. Induction of apoptotic cell death in human endothelial cells treated with snake venom: Implication of intracellular reactive oxygen species and protective effects of glutathione and superoxide dismutases. J Biochem (Tokyo) 122: 1260-64, 1997.
391. Suzuki S, Kumatori A, Haagen IA, Fujii Y, Sadat MA, Jun HL, Tsuji Y, Roos D, Nakamura M. PU.1 as an essential activator for the expression of gp91phox gene in human peripheral neutrophils, monocytes, and B lymphocytes. Proc Natl Acad Sci U S A 95: 6085-90, 1998.
392. Suzuki Y, Ono Y, Hirabayashi Y. Rapid and specific reactive oxygen species generation via NADPH oxidase activation during Fas-mediated apoptosis. FEBS Lett 425: 209-12, 1998.
393. Szabo C, Cuzzocrea S, Zingarelli B, O'Connor M, Salzman AL. Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J Clin Invest 100: 723-35, 1997.
394. Tal T, Aviram I. Defensin interferes with the activation of neutrophil NADPH oxidase in a cell-free system. Biochem Biophys Res Commun 196: 636-41, 1993.
395. Tal T, Sharabani M, Aviram I, Michaela S, Irit A. Cationic proteins of neutrophil azurophilic granules: Protein-protein interaction and blockade of NADPH oxidase activation. J Leukoc Biol 63: 305-11, 1998.
396. Tapon N, Hall A. Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr Opin Cell Biol 9: 86-92, 1997.
397. Tauber AI, Borregaard N, Simons E, Wright J. Chronic granulomatous disease: A syndrome of phagocyte oxidase deficiencies. Medicine (Baltimore) 62: 286-309, 1983.
398. Taylor WR, Jones DT, Segal AW. A structural model for the nucleotide binding domains of the flavocytochrome b-245 beta-chain. Protein Sci 2: 1675-85, 1993.
399. Teahan C, Rowe P, Parker P, Totty N, Segal AW. The X-linked chronic granulomatous disease gene codes for the beta-chain of cytochrome b-245. Nature 327: 720-21, 1987.
400. Thrasher A, Chetty M, Casimir C, Segal AW. Restoration of superoxide generation to a chronic granulomatous disease-derived B-cell line by retrovirus mediated gene transfer. Blood 80: 1125-29, 1992.
401. Thrasher AJ, Casimir CM, Kinnon C, Morgan G, Segal AW, Levinsky RJ. Gene transfer to primary chronic granulomatous disease monocytes. Lancet 346: 92-93, 1995.
402. Thrasher AJ, Keep NH, Wientjes F, Segal AW. Chronic granulomatous disease. Biochim Biophys Acta 1227: 1-24, 1994.
403. Tsunawaki S, Mizunari H, Nagata M, Tatsuzawa O, Kuratsuji T. A novel cytosolic component, p40phox, of respiratory burst oxidase associates with p67phox and is absent in patients with chronic granulomatous disease who lack p67phox. Biochem Biophys Res Commun 199: 1378-87, 1994.
404. van't Hek LG, Verweij PE, Weemaes CM, van Dalen R, Yntema JB, Meis JF. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med 157: 1694-96, 1998.
405. Varma VA, Sessions JT, Kahn LB, Lipper S. Chronic granulomatous disease of childhood presenting as gastric outlet obstruction. Am J Surg Pathol 6: 673-76, 1982.
406. Verhaegen S, McGowan AJ, Brophy AR, Fernandes RS, Cotter TG. Inhibition of apoptosis by antioxidants in the human HL-60 leukemia cell line. Biochem Pharmacol 50: 1021-29, 1995.
407. Volpp BD, Lin Y. In vitro molecular reconstitution of the respiratory burst in B lymphoblasts from p47-phox-deficient chronic granulomatous disease. J Clin Invest 91: 201-7, 1993.
408. Volpp BD, Nauseef WM, Clark RA. Two cytosolic neutrophil oxidase components absent in autosomal chronic granulomatous disease. Science 242: 1295-97, 1988.
409. Volpp BD, Nauseef WM, Donelson JE, Moser DR, Clark RA. Cloning of the cDNA and functional expression of the 47-kilodalton cytosolic component of human neutrophil respiratory burst oxidase. Proc Natl Acad Sci U S A 86: 7195-99, 1989.
410. von Planta M, Ozsahin H, Schroten H, Stauffer UG, Seger RA. Greater omentum flaps and granulocyte transfusions as combined therapy of liver abscess in chronic granulomatous disease. Eur J Pediatr Surg 7: 234-36, 1997.
411. Vowells SJ, Fleisher TA, Malech HL. Testing for chronic granulomatous disease [letter and comment]. Lancet 347: 1048-49, 1996.
412. Vowells SJ, Fleisher TA, Sekhsaria S, Ailing DW, Maguire TE, Malech HL. Genotype-dependent variability in flow cytometric evaluation of reduced nicotinamide adenine dinucleotide phosphate oxidase function in patients with chronic granulomatous disease. J Pediatr 128: 104-7, 1996.
413. Vowells SJ, Sekhsaria S, Malech HL, Shalit M, Fleisher TA. Flow cytometric analysis of the granulocyte respiratory burst: A comparison study of fluorescent probes. J Immunol Methods 178: 89-97, 1995.
414. Waite KA, Wallin R, Qualliotine-Mann D, McPhail LC. Phosphatidic acid-mediated phosphorylation of the NADPH oxidase component p47-phox. Evidence that phosphatidic acid may activate a novel protein kinase. J Biol Chem 272: 15569-78, 1997.
415. Walder CE, Green SP, Darbonne WC, Mathias J, Rae J, Dinauer MC, Curnutte JT, Thomas GR. Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase. Stroke 28: 2252-58, 1997.
416. Wallach TM, Segal AW. Analysis of glycosylation sites on gp91phox, the flavocytochrome of the NADPH oxidase, by site-directed mutagenesis and translation in vitro. Biochem J 321: 583-85, 1997.
417. Walther MM, Malech H, Berman A, Choyke P, Venzon DJ, Linehan WM, Gallin JI. The urological manifestations of chronic granulomatous disease. J Urol 147: 1314-18, 1992.
418. Wang HD, Pagano PJ, Du Y, Cayatte AJ, Quinn MT, Brecher P, Cohen RA. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 82: 810-18, 1998.
419. Watson RW, Rotstein OD, Nathens AB, Dackiw AP, Marshall JC. Thiolmediated redox regulation of neutrophil apoptosis. Surgery 120: 150-57 [discussion 157-58], 1996.
420. Weening RS, Corbeel L, de Boer M, Lutter R, van Zwieten R, Hamers MN, Roos D. Cytochrome b deficiency in an autosomal form of chronic granulomatous disease. A third form of chronic granulomatous disease recognized by monocyte hybridization. J Clin Invest 75: 915-20, 1985.
421. Weening RS, Kabel P, Pijman P, Roos D. Continuous therapy with sulfamethoxazole-trimethoprim in patients with chronic granulomatous disease. J Pediatr 103: 127-30, 1983.
422. Weil WM, Linton GF, Whiting-Theobald N, Vowells SJ, Rafferty SP, Li F, Malech HL. Genetic correction of p67phox deficient chronic granulomatous disease using peripheral blood progenitor cells as a target for retrovirus mediated gene transfer. Blood 89: 1754-61, 1997.
423. Wells PG, Kim PM, Laposa RR, Nicol CJ, Parman T, Winn LM. Oxidative damage in chemical teratogenesis. Mutat Res 396: 65-78, 1997.
424. Werlin SL, Chusid MJ, Caya J, Oechler HW. Colitis in chronic granulomatous disease. Gastroenterology 82: 328-31, 1982.
425. White CJ, Kwon-Chung KJ, Gallin JI. Chronic granulomatous disease of childhood. An unusual case of infection with Aspergillus nidulans var. echinulatus. Am J Clin Pathol 90: 312-16, 1988.
426. Widger WR, Cramer WA, Herrmann RG, Trebst A. Sequence homology and structural similarity between cytochrome b of mitochondrial complex III and the chloroplast b6-f complex: Position of the cytochrome b hemes in the membrane. Proc Natl Acad Sci U S A 81: 674-78, 1984.
427. Wientjes FB, Hsuan JJ, Totty NF, Segal AW. p40phox, a third cytosolic component of the activation complex of the NADPH oxidase to contain src homology 3 domains. Biochem J 296: 557-61, 1993.
428. Wientjes FB, Segal AW, Hartwig JH. Immunoelectron microscopy shows a clustered distribution of NADPH oxidase components in the human neutrophil plasma membrane. J Leukoc Biol 61: 303-12, 1997.
429. Williamson PR, Kwon-Chung KJ, Gallin JI. Successful treatment of Paecilomyces varioti infection in a patient with chronic granulomatous disease and a review of Paecilomyces species infections. Clin Infect Dis 14: 1023-26, 1992.
430. Windhorst DB, Holmes B, Good RA. A newly defined X-linked trait in man with demonstration of the Lyon effect in carrier females. Lancet 1: 737-39, 1967.
431. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, Malech HL, Holland SM, Ochs H, Quie P, Buckley RH, Foster CB, Chanock SJ, Dickler H. Chronic granulomatous disease: Report on a national registry of 368 patients. Medicine (Baltimore) 79: 155-69, 2000.
432. Woodman RC, Erickson RW, Rae J, Jaffe HS, Curnutte JT. Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: Evidence against enhanced neutrophil oxidase activity. Blood 79: 1558-62, 1992.
433. Yeaman GR, Froebel K, Galea G, Ormerod A, Urbaniak SJ. Discoid lupus erythematosus in an X-linked cytochrome-positive carrier of chronic granulomatous disease. Br J Dermatol 126: 60-65, 1992.
434. Yomtovian R, Abramson J, Quie P, McCullough J. Granulocyte transfusion therapy in chronic granulomatous disease. Report of a patient and review of the literature. Transfusion 21: 739-43, 1981.
435. Yoshida LS, Saruta F, Yoshikawa K, Tatsuzawa O, Tsunawaki S. Mutation at histidine 338 of gp91phox depletes FAD and affects expression of cytochrome b558 of the human NADPH oxidase. J Biol Chem 273: 27879-86, 1998.
436. Yu L, DeLeo FR, Biberstine-Kinkade KJ, Renee J, Nauseef WM, Dinauer MC. Biosynthesis of flavocytochrome b558. Gp91phox is synthesized as a 65-kda precursor (p65) in the endoplasmic reticulum. J Biol Chem 274: 4364-69, 1999.
437. Yu L, Quinn MT, Cross AR, Dinauer MC. Gp91phox is the heme binding subunit of the superoxide-generating NADPH oxidase. Proc Natl Acad Sci U S A 95: 7993-98, 1998.
438. Zhan S, Vazquez N, Wientjes FB, Budarf ML, Schrock E, Ried T, Green ED, Chanock SJ. Genomic structure, chromosomal localization, start of transcription, and tissue expression of the human p40-phox, a new component of the nicotinamide adenine dinucleotide phosphate-oxidase complex. Blood 88: 2714-21, 1996.
439. Zhang DE, Hetherington CJ, Chen HM, Tenen DG. The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. Mol Cell Biol 14: 373-81, 1994.
440. Zhen L, Yu L, Dinauer MC. Probing the role of the carboxyl terminus of the gp91phox subunit of neutrophil flavocytochrome b558 using site-directed mutagenesis. J Biol Chem 273: 6575-81, 1998.